Copyright
©The Author(s) 2023.
World J Cardiol. Jan 26, 2023; 15(1): 23-32
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.23
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.23
Variable | Events (16/183) | Routine (3-24 h) | Events (21/154) | Delayed (> 24 h) |
OR (95%CI) | OR (95%CI) | |||
Age (> 65 yr) | 1/16 | 0.68 (0.08-5.48) | 3/18 | 1.31 (0.34-4.98) |
Age (55-65 yr) | 9/81 | 1.70 (0.62-4.77) | 8/47 | 1.48 (0.57-3.86) |
Age (45-55 yr) | 1/41 | 0.21 (0.03-1.65) | 5/56 | 0.50 (0.17-1.46) |
Age (35-45 yr) | 4/38 | 1.30 (0.40-4.30) | 4/26 | 1.19 (0.36-3.87) |
Age (< 35 yr) | 1/7 | 1.79 (0.20-15.86) | 1/7 | 1.06 (0.12-9.26) |
Male | 15/160 | 2.28 (0.29-18.10) | 17/138 | 0.42 (0.12-1.46) |
KILLIP Class-1 | 13/165 | 0.43 (0.11-1.67) | 17/132 | 0.67 (0.20-2.20) |
KILLIP Class-2 | 3/11 | 4.59 (1.08-19.40) | 1/9 | 0.78 (0.09-6.59) |
AWMI | 9/99 | 1.10 (0.39-3.09) | 10/88 | 0.64(0.25-1.61) |
Type 2 DM | 3/37 | 0.9 (0.24-3.35) | 2/34 | 0.33(0.07-1.50) |
Smoking | 10/100 | 1.43 (0.50-4.10) | 14/86 | 1.69 (0.64-4.47) |
HTN | 4/49 | 0.90 (0.28-2.95) | 4/43 | 0.57 (0.18-1.79) |
LVEF (35-45) | 3/70 | 0.34 (0.09-1.25) | 7/73 | 0.51 (0.19-1.34) |
LVEF (> 45) | 12/112 | 2.01 (0.62-6.50) | 14/78 | 2.16 (0.82-5.68) |
MVD | 7/78 | 1.05 (0.37-2.96) | 11/65 | 1.61 (0.64-4.05) |
SVD | 9/98 | 1.13 (0.40-3.17) | 10/87 | 0.66 (0.26-1.66) |
CrCl (30-60) | 1/29 | 0.33 (0.04-2.61) | 5/30 | 1.35 (0.45-4.03) |
CrCl (60-90) | 11/113 | 1.40 (0.47-4.22) | 11/78 | 1.08 (0.43-2.72) |
CrCl (> 90) | 4/40 | 1.21 (0.37-3.99) | 5/42 | 0.81 (0.28-2.37) |
- Citation: Sethi R, Mohan L, Vishwakarma P, Singh A, Sharma S, Bhandari M, Shukla A, Sharma A, Chaudhary G, Pradhan A, Chandra S, Narain VS, Dwivedi SK. Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction. World J Cardiol 2023; 15(1): 23-32
- URL: https://www.wjgnet.com/1949-8462/full/v15/i1/23.htm
- DOI: https://dx.doi.org/10.4330/wjc.v15.i1.23